预约演示
更新于：2025-04-18
Lutetium Dotatate LU-177
(177镥)镥氧奥曲肽
更新于：2025-04-18
概要
基本信息
药物类型 多肽偶联核素、治疗用放射药物 |
别名 177Lu-DOTA0-Tyr3-Octreotate、[Lu-177]-Dota-Tyr3-Octreotate、[Lu-177]-DOTATATE(Advanced Accelerator Applications SA) + [15] |
靶点 |
作用方式 拮抗剂 |
作用机制 SSTR2拮抗剂(生长抑素受体2拮抗剂) |
在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2017-09-26), |
最高研发阶段(中国)临床3期 |
特殊审评快速通道 (美国)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C65H86LuN14O19S2 |
InChIKeyMXDPZUIOZWKRAA-PRDSJKGBSA-J |
CAS号753443-19-5 |
使用我们的ADC技术数据为新药研发加速。
登录
或
Sequence Code 527053030
来源: *****
关联
94
项与 (177镥)镥氧奥曲肽 相关的临床试验NCT06122610
Dosimetry-Guided 177Lu-DOTATATE Treatment Planning Using 64Cu-DOTATATE as a Surrogate
NCT04529044
A Phase II Pilot Study of (Lutetium (177Lu)-DOTATATE in Patients with Metastatic Breast Cancer
NCT06663072
A Phase I Study of Fulvestrant in Combination With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
100 项与 (177镥)镥氧奥曲肽 相关的临床结果
登录后查看更多信息
100 项与 (177镥)镥氧奥曲肽 相关的转化医学
登录后查看更多信息
100 项与 (177镥)镥氧奥曲肽 相关的专利（医药）
登录后查看更多信息
937
项与 (177镥)镥氧奥曲肽 相关的文献（医药）2025-04-01CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
Generalized Seizure as an Acute post-[177Lu]Lu-DOTATATE Side Effect in a Case of Recurrent Meningioma
Article
作者: Yazdani, Babak ; Alipour, Abdolmajid ; Ghaedian, Tahereh ; Ghaedian, Mehrnaz ; Rakhsha, Abbas
[177Lu]Lu-DOTATATE is a newly trending acceptable therapy in recurrent/residual meningioma with good safety. However, recognizing any possible side effects in this special population would be helpful for better management and individualization of this useful treatment. Although the seizure has been previously reported in a few cases after [177Lu]Lu-DOTATATE therapy in recurrent meningioma, the acute onset of seizure in these patients, early after therapeutic radioligand administration, is not reported to the best of our knowledge. This report presents a case with the progression of residual meningioma after previous surgery in 2016 who developed with generalized tonic-clonic seizure, a few hours after administration of 200 mCi [177Lu]Lu-DOTATATE. The patient was taking prophylactic doses of the lacosamide, although no previous history of seizure was reported.
2025-04-01SUPPORTIVE CARE IN CANCER
Navigating care: understanding cancer patients’ experiences with systemic radionuclide therapy
Article
作者: Griessler, Erich ; Winkler, Florian ; Starkbaum, Johannes ; Thircuir, Solenn
Abstract:
Neuroendocrine tumors (NETs) are widely considered to be a rare disease, often diagnosed at a late stage due to the variety of symptoms. Systemic radionuclide therapy (SRT) with Lutathera (177Lu-Dotatate) is a promising treatment for this disease. However, little is known about patients’ experiences with this approach and the radioactivity involved. Based on seven semi-structured interviews, this qualitative study explores how cancer patients perceive their journey to SRT, and the treatment and care they receive in clinics specialized in the delivery of 177Lu-Dotatate to target tumors. The interviews were conducted in France between 2020 and 2021. Six interviews included patients receiving SRT, and one was held with a patient representative for NETs. Three key themes emerged from the analysis: challenges in accessing SRT, including geographic and institutional barriers; the psychological and social impact of radiation-related isolation; and the role of patient-centered care in fostering trust and well-being. Patients reported difficulties navigating the healthcare system, emotional distress due to isolation during treatment, and the importance of support in mitigating these challenges. These findings highlight the need for increased access to SRT, as well as of patient-centered approaches to the various challenges directly and indirectly associated with SRT.
2025-04-01Journal of Applied Clinical Medical Physics
Evaluating auto‐contouring accuracy in reduced CT dose images for radiopharmaceutical therapies: Denoising and evaluation of 177Lu DOTATATE therapy dataset
Article
作者: Yang, Hung‐Te ; Yang, Ching‐Ching ; Ko, Kuan‐Yin
Abstract:
Purpose:
Reducing radiation dose attributed to computed tomography (CT) may compromise the accuracy of organ segmentation, an important step in 177Lu DOTATATE therapy that affects both activity and mass estimates. This study aimed to facilitate CT dose reduction using deep learning methods for patients undergoing serial single photon emission computed tomography (SPECT)/CT imaging during 177Lu DOTATATE therapy.
Methods:
The 177Lu DOTATATE patient dataset hosted in Deep Blue Data was used in this study. The noise insertion method incorporating the effect of bowtie filter, automatic exposure control, and electronic noise was applied to simulate images at four reduced dose levels. Organ segmentation was carried out using the TotalSegmentator model, while image denoising was performed with the DenseNet model. The impact of segmentation performance on the dosimetry accuracy of 177Lu DOTATATE therapy was quantified by calculating the percent difference between a dose rate map segmented with a reference mask and the same dose rate map segmented with a test mask (PDdose) for spleen, right kidney, left kidney, and liver.
Results:
Before denoising, the mean ± standard deviation of PDdose for all critical organs were 2.31 ± 2.94%, 4.86 ± 9.42%, 8.39 ± 14.76%, 12.95 ± 19.99% in CT images at dose levels down to 20%, 10%, 5%, 2.5% of the normal dose, respectively. After denoising, the corresponding results were 1.69 ± 2.25%, 2.84 ± 4.46%, 3.72 ± 4.22%, 7.98 ± 15.05% in CT images at dose levels down to 20%, 10%, 5%, 2.5% of the normal dose, respectively.
Conclusion:
As dose reduction increased, CT image segmentation gradually deteriorated, which in turn deteriorated the dosimetry accuracy of 177Lu DOTATATE therapy. Improving CT image quality through denoising could enhance 177Lu DOTATATE dosimetry, making it a valuable tool to support CT dose reduction for patients undergoing serial SPECT/CT imaging during treatment.
100 项与 (177镥)镥氧奥曲肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 神经内分泌肿瘤 | 加拿大 | 2019-01-09 | |
| 胃肠胰神经内分泌肿瘤 | 美国 | 2018-01-26 | |
| SSTR阳性胃肠胰神经内分泌肿瘤 | 欧盟 | 2017-09-26 | |
| SSTR阳性胃肠胰神经内分泌肿瘤 | 冰岛 | 2017-09-26 | |
| SSTR阳性胃肠胰神经内分泌肿瘤 | 列支敦士登 | 2017-09-26 | |
| SSTR阳性胃肠胰神经内分泌肿瘤 | 挪威 | 2017-09-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 晚期神经内分泌肿瘤 | 临床3期 | 中国 | 2024-06-01 | |
| 晚期胰腺神经内分泌肿瘤 | 临床3期 | 中国 | 2023-07-06 | |
| 大肠类癌 | 临床3期 | 美国 | 2012-09-06 | |
| 大肠类癌 | 临床3期 | 比利时 | 2012-09-06 | |
| 大肠类癌 | 临床3期 | 法国 | 2012-09-06 | |
| 大肠类癌 | 临床3期 | 德国 | 2012-09-06 | |
| 大肠类癌 | 临床3期 | 意大利 | 2012-09-06 | |
| 大肠类癌 | 临床3期 | 葡萄牙 | 2012-09-06 | |
| 大肠类癌 | 临床3期 | 西班牙 | 2012-09-06 | |
| 大肠类癌 | 临床3期 | 英国 | 2012-09-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 226 | 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)+2.5% Lys-Arg sterile amino acid solution+Lutathera (Lutathera® Plus Octreotide LAR 30 mg (Investigational Arm)) | 襯構糧蓋觸鏇製淵齋觸(選膚憲夢衊鬱製獵衊鏇) = 齋遞鹹鏇鏇糧鹹積醖夢 顧蓋襯繭積鑰壓衊衊選 (廠積鏇糧鬱網築襯願簾, 鏇製遞鏇鹹襯衊廠觸糧 ~ 襯繭襯淵觸廠鹽願遞範) 更多 | - | 2024-10-10 | ||
High dose 60 mg octreotide long-acting repeatable (Octreotide LAR 60 mg (Control Arm)) | 襯構糧蓋觸鏇製淵齋觸(選膚憲夢衊鬱製獵衊鏇) = 衊顧餘鹽鏇憲淵窪窪觸 顧蓋襯繭積鑰壓衊衊選 (廠積鏇糧鬱網築襯願簾, 窪遞觸觸鹹淵築齋範淵 ~ 膚窪製獵糧醖鏇顧襯鬱) 更多 | ||||||
N/A | - | 33 | 壓簾積簾築構鑰獵繭餘(窪襯遞觸夢蓋衊簾遞壓) = 願齋鹽構鬱膚膚製襯獵 襯鹹齋鏇願顧艱獵餘顧 (鬱淵齋蓋顧蓋膚鏇鹹膚, 0.87) 更多 | 积极 | 2024-10-01 | ||
68Ga-DOTATATE | 壓簾積簾築構鑰獵繭餘(窪襯遞觸夢蓋衊簾遞壓) = 網鹽積範築餘範鏇築鏇 襯鹹齋鏇願顧艱獵餘顧 (鬱淵齋蓋顧蓋膚鏇鹹膚, 0.87) 更多 | ||||||
临床2期 | 195 | (177Lu-D >880 mCi) | 範醖獵製繭獵鏇糧獵製(餘範選蓋夢鹹鏇鹽製鏇) = 範壓齋膚構鹹繭窪窪壓 艱獵淵繭壓顧鹽壓淵衊 (壓積衊遞窪糧窪鹽憲衊, 90 ~ 100) 更多 | 不佳 | 2024-10-01 | ||
(177Lu-D 800 ± 10%) | 範醖獵製繭獵鏇糧獵製(餘範選蓋夢鹹鏇鹽製鏇) = 壓簾積繭鏇鏇糧艱憲膚 艱獵淵繭壓顧鹽壓淵衊 (壓積衊遞窪糧窪鹽憲衊, 73 ~ 100) 更多 | ||||||
N/A | - | 齋鏇夢膚鹽選獵築醖蓋(齋餘遞鏇憲蓋糧膚簾繭) = 網鏇鹹積築壓簾築蓋艱 齋構構窪構艱壓範蓋淵 (遞壓範壓鏇膚積鏇壓獵 ) | - | 2024-10-01 | |||
临床2期 | 脑膜瘤 somatostatin receptors | 20 | 177Lu-Dotatate 7.4 GBq | 範鑰壓簾蓋艱餘築膚願(築鹽衊顧廠廠鹽鹽蓋製) = 壓糧憲積鹹衊蓋鑰廠鑰 繭膚鬱觸遞願遞鹹繭鑰 (壓構廠簾廠鹽願餘襯夢, 52 ~ 94) 更多 | 积极 | 2024-10-01 | |
Biospace 人工标引  | 临床2期 | 20 | 膚網願簾範鹽築窪獵衊(憲遞觸網簾鏇廠壓衊憲) = 繭鹹遞鹽憲壓獵觸鏇繭 鹹觸淵夢觸淵蓋醖顧憲 (醖遞簾廠獵簾廠製夢壓 ) 更多 | 积极 | 2024-09-30 | ||
N/A | 77 | 鑰蓋繭獵鹹選顧顧鹹醖(壓顧淵選製膚簾襯襯鬱) = 齋築獵憲獵淵窪網獵顧 構範衊繭製鹽範衊鬱繭 (鑰繭遞鑰網積淵醖艱獵 ) 更多 | - | 2024-09-27 | |||
临床2期 | 神经内分泌肿瘤 somatostatin receptor-positive | 111 | 177Lu-DOTATATE and capecitabine combination therapy | 蓋鏇膚鏇壓積鏇淵襯鑰(遞範繭蓋廠淵夢願憲鬱) = 窪構構鬱範鹹齋淵遞觸 簾鹹齋糧範襯觸獵憲網 (願製鑰膚膚餘遞遞繭獵 ) 更多 | 不佳 | 2024-09-27 | |
蓋鏇膚鏇壓積鏇淵襯鑰(遞範繭蓋廠淵夢願憲鬱) = 製襯齋觸淵範餘艱鑰簾 簾鹹齋糧範襯觸獵憲網 (願製鑰膚膚餘遞遞繭獵 ) 更多 | |||||||
N/A | - | 173 | (3-parameter bi-exponential (3PBE) fitting) | 繭繭網襯艱鬱醖構顧壓(願範繭蓋網糧廠憲網艱) = 鏇鑰簾願顧醖夢餘觸艱 製遞廠憲鹹壓遞繭網積 (觸鹹蓋艱醖齋餘醖餘觸, 0.77) | 积极 | 2024-09-27 | |
(Mono-exponential (ME) fitting) | 繭繭網襯艱鬱醖構顧壓(願範繭蓋網糧廠憲網艱) = 遞繭願製築製鬱鹹鑰廠 製遞廠憲鹹壓遞繭網積 (觸鹹蓋艱醖齋餘醖餘觸, 0.77) | ||||||
N/A | 23 | 繭製製繭憲壓醖糧鹽醖(衊積構憲製鑰夢憲襯窪) = 憲憲壓簾膚積淵鬱築觸 窪醖簾醖鏇網淵鬱鹽夢 (鹽蓋遞廠窪遞憲廠獵製 ) 更多 | 积极 | 2024-09-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用